Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting

Jun 6, 2022 | Press Releases

MARLBOROUGH, Mass., June 6, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022

May 16, 2022 | Press Releases

MARLBOROUGH, Mass., May 16, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

May 12, 2022 | Press Releases

First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the second half of 2022 MARLBOROUGH, Mass., May 12, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a...

Phio Pharmaceuticals Announces Senior Leadership Personnel Change

May 5, 2022 | Press Releases

MARLBOROUGH, Mass., May 5, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced...

Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022

May 3, 2022 | Press Releases

MARLBOROUGH, Mass., May 3, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced...